Key Takeaway: MeiraGTx announced its second quarter 2026 financial and operational results, highlighting the receipt of FDA Breakthrough Therapy Designation for AAV2-hAQP1. The company also reported encouraging three-year data from its Phase 1 AQUAx clinical trial, which evaluates AAV2-hAQP1 for treating moderate to severe radiation-induced xerostomia. Additionally, MeiraGTx completed the acquisition of all interests and rights related to this treatment.
Market Sentiment Analysis
POSITIVE FACTORS
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1.
Reported positive three-year data from Phase 1 AQUAx trial.
Acquisition of all interests and rights completed.
Full Press Release Details
Received FDA Breakthrough Therapy Designation for AAV2-hAQP1 and reported positive three-year data from Phase 1 AQUAx clinical trial evaluating AAV2-hAQP1 for the treatment of moderate to severe grade 2/3 radiation-induced xerostomia Completed the acquisition of all interests and rights to
Frequently Asked Questions
What designation did MeiraGTx receive for AAV2-hAQP1?
MeiraGTx received FDA Breakthrough Therapy Designation for AAV2-hAQP1.
What were the results from the Phase 1 AQUAx trial?
The Phase 1 AQUAx trial reported positive three-year data for AAV2-hAQP1.
What acquisition did MeiraGTx complete?
MeiraGTx completed the acquisition of all interests and rights related to AAV2-hAQP1.